A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults
- 1 May 1985
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 142 (5), 547-552
- https://doi.org/10.1176/ajp.142.5.547
Abstract
Thirty-seven adult patients meeting the Utah criteria for attention deficit disorder, residual type, were entered into a double-blind crossover trial of methylphenidate and placebo. A moderate-to-marked therapeutic response occurred in 21 (57%) of the patients while receiving methylphenidate and in 4 (11%) while receiving placebo, a highly significant difference statistically and clinically. The responding patients showed significant improvement in the following areas: attentional difficulty, motor overactivity, affective lability and impulsivity. The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.This publication has 9 references indexed in Scilit:
- Organic Brain Dysfunction and the Borderline SyndromePsychiatric Clinics of North America, 1981
- Attention Deficit Disorder ('Minimal Brain Dysfunction') in AdultsArchives of General Psychiatry, 1981
- Diagnosis and Treatment of Minimal Brain Dysfunction in AdultsArchives of General Psychiatry, 1976
- The Global Assessment ScaleArchives of General Psychiatry, 1976
- The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report ScaleThe British Journal of Psychiatry, 1976